LATEST
Frutas Y Hortalizas Del Sur S.A. Expands Recalls to Include Additional Lots of Great Value Frozen Organic Triple Berry Blend 10 OZ, Great Value Frozen Organic Blueberries 10 OZ and One Lot of Trader Joe’s Frozen Organic Mixed Berry Blend 12 OZ Because of Potential Contamination with Escherichia ColiMultilocal Secures Backing of OAREX to Accelerate Global Growth with New CapitalDea Schedule I Proposal Would Criminalize Compound with Breakthrough Therapy Status for Postpartum DepressionFull-Body Mirrored Adult-Sized Humanoid Robots Fighting in Real-Time for the First TimeCHASING CanFish F2 Heads to Kickstarter, Introducing a New Way to Scout the WaterEurope Turns to Private Enterprise to Close the Gap as BOARD Attracts Support from Over 200 European CEOsStudent Innovators Advance Their Robotic Projects at World Robot Olympiad Entrepreneur Program from Competition to Startup StageAfter Historic FDA Hearing On Psychedelic Therapies, Grassroots Student Group Mobilizes To Shape What Comes NextGaza Anger Breaks Old Political Loyalties in Britain and BeyondChristopher Columbus Identified As A Portuguese Prince In New InvestigationFrutas Y Hortalizas Del Sur S.A. Expands Recalls to Include Additional Lots of Great Value Frozen Organic Triple Berry Blend 10 OZ, Great Value Frozen Organic Blueberries 10 OZ and One Lot of Trader Joe’s Frozen Organic Mixed Berry Blend 12 OZ Because of Potential Contamination with Escherichia ColiMultilocal Secures Backing of OAREX to Accelerate Global Growth with New CapitalDea Schedule I Proposal Would Criminalize Compound with Breakthrough Therapy Status for Postpartum DepressionFull-Body Mirrored Adult-Sized Humanoid Robots Fighting in Real-Time for the First TimeCHASING CanFish F2 Heads to Kickstarter, Introducing a New Way to Scout the WaterEurope Turns to Private Enterprise to Close the Gap as BOARD Attracts Support from Over 200 European CEOsStudent Innovators Advance Their Robotic Projects at World Robot Olympiad Entrepreneur Program from Competition to Startup StageAfter Historic FDA Hearing On Psychedelic Therapies, Grassroots Student Group Mobilizes To Shape What Comes NextGaza Anger Breaks Old Political Loyalties in Britain and BeyondChristopher Columbus Identified As A Portuguese Prince In New Investigation
Technology

SOPHION and CREACELL Announced Today That the Two Companies Successfully Demonstrated the Performances of HEK-hKir2.1 Cells on QPatch HT

Richard Powell  2 min read
Illustration: greatreporter

SOPHION and CREACELL announced today that the two companies successfully demonstrated the performances of HEK-hKir2.1 cells on QPatch HT.

Inward rectifier potassium channels of the Kir2 subfamily are important determinants of the electrical activity of cardiac cells, and mutations of the Kir2.1 channels are associated with familial atrial fibrillation, Andersen-Tawil syndrome and short-QT syndrome.

Because human Kir2.1 is a relevant target in preclinical cardiac safety testing of drug compounds, SOPHION and CREACELL demonstrate the functionality of the CreaCell's HEK-hKir2.1 recombinant cell line on Sophion's automated patch-clamp system QPatch HT. Current amplitudes, IV curves, Ba2+ currents, and chloroethylclonidine dose-response curves were analysed.

“Several of our customers have asked us for a QPatch-optimized cell line expressing clinically relevant hKir2.1 ion channels,” said Dr. Morten Sunesen, VP of Customer Relations at Sophion. “We are pleased to announce the first result of this fruitful collaboration with CreaCell and our customers will benefit.”

“The synergy between our two companies is natural and allows us to satisfy client demands” said Dr. Pierre-Yves Perche, CEO at CreaCell. “At the same time, through this partnership with Sophion and its extensive network of customers, CreaCell confirms its intentions of developing its position in the worldwide market.”

To access the Application Report, please click on the following link: http://www.sophion.com/media/31412/hek-hkir2.1.pdf

Sophion Bioscience, a leader in the automated patch clamp field, helps the pharmaceutical industry develop more and better drugs, faster. Sophion’s focus is to provide advanced products and integrated solutions for automated patch clamping. Sophion’s QPatch family of products provides high-quality patch clamp data on a truly industrial basis on all types of ion channels. Recently Sophion became part of Biolin Scientific, a Swedish materials science company providing high-tech precision instruments for research within surface-, material- and bio-science, drug discovery and diagnostic applications.

CreaCell is a Products and Services company that provides innovative cell-based solutions to the pharmaceutical industry for drug discovery and drug safety. CreaCell's expertise is exploited in two main areas: i-CreaCell offers Licence agreement for its Ion Channel Cell Lines, ii-Through its Cell Culture Services, CreaCell offers solutions for custom development, production and characterization of recombinant cell lines. The company has established several partnerships and license agreements with world leaders in these sectors.

Related articles

Top